Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical TransplantationYing-Jun Chang, Lan-Ping Xu, Yu Wang, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|December 16, 2020
Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host diseaseTing-Ting Han, Yi-Ning Zhang, Yu-Qian Sun, et al.
Cellular & Molecular Immunology|January 12, 2022
Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantationXu-Ying Pei, Xue-Fei Liu, Xiang-Yu Zhao, et al.
International Journal of Cardiology|June 26, 2012
Heart failure after allogeneic hematopoietic stem cell transplantationXiao-Dong Mo, Lan-Ping Xu, Dai-Hong Liu, et al.
Leukemia Research|May 31, 2016
Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemiaFei-Fei Tang, Xiao-Jun Huang, Xiao-Hui Zhang, et al.
Bone Marrow Transplantation|March 24, 2019
Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantationZheng-Li Xu, Lan-Ping Xu, Yuan-Yuan Zhang, et al.
Medcomm|January 19, 2026
Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell TransplantationZheng-Li Xu, Meng Lv, Xing-Xing Yu, et al.
Haematologica|October 12, 2023
Targeting TFH cells is a novel approach for donor-specific antibody desensitization of allograft candidates: an in vitro and in vivo studyNing Ma, Wei-Bing Wu, Xiang-Yu Zhao, et al.
Cancer Communications (London, England)|October 24, 2022
Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long-term clinical outcomes and health-related quality of life assessmentChen-Hua Yan, Yu Wang, Yu-Qian Sun, et al.
Blood Cell Therapy|June 9, 2025
PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantationLing Ma, Si-Qi Li, Wei Han, et al.
Pageof 14